Cabozantinib in genitourinary malignancies.
Sign Up to like & getrecommendations! Published in 2017 at "Future oncology"
DOI: 10.2217/fon-2016-0358
Abstract: Cabozantinib inhibits a variety of cellular receptors including VEGFR1-3, MET, AXL, RET, FLT3 and KIT. These signaling pathways have been shown to be important in genitourinary malignancies. Along its clinical development, it has shown most… read more here.
Keywords: oncology; carcinoma; cabozantinib genitourinary; genitourinary malignancies ... See more keywords